Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ASO Visual Abstract: Long-Term Outcomes of Patients with Gastric Cancer and Positive Peritoneal Cytology.

Annals of surgical oncology·2026
Same author

Long-Term Outcomes of Patients with Gastric Cancer and Positive Peritoneal Cytology.

Annals of surgical oncology·2026
Same author

Pressure enabled drug delivery (PEDD) of nelitolimod increased therapeutic delivery, reduced immunosuppression, and improved efficacy in porcine and murine liver tumor models.

Frontiers in oncology·2025
Same author

Genomic Signatures of Gastric Adenocarcinoma By Tumor Location-Modified Laurén Classification: Highlighting the Molecular Heterogeneity of Mixed-Type Tumors.

The American journal of surgical pathology·2025
Same author

Merkel Cell Carcinoma: Current Treatment Landscape and Emerging Therapeutic Targets.

Current oncology reports·2025
Same author

Pressure-Enabled Drug Delivery Significantly Increases Intra-Arterial Delivery of Embolic Microspheres to Liver Tumors in a Porcine Model.

Journal of vascular and interventional radiology : JVIR·2024

Related Experiment Video

Updated: Jun 18, 2026

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies

Published on: July 28, 2020

Randomized clinical trials in soft tissue sarcoma.

Steven C Katz1, Murray F Brennan

  • 1Department of Surgery, Roger Williams Medical Center, 825 Chalkstone Avenue, Providence, RI 02908, USA.

Surgical Oncology Clinics of North America
|November 17, 2009
PubMed
Summary
This summary is machine-generated.

Soft tissue sarcomas (STS) are rare cancers. Recent studies offer limited new randomized controlled trials (RCTs), necessitating a critical review of existing data for effective soft tissue sarcoma management.

More Related Videos

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

Related Experiment Videos

Last Updated: Jun 18, 2026

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies

Published on: July 28, 2020

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

Area of Science:

  • Oncology
  • Pathology
  • Medical Research

Background:

  • Soft tissue sarcomas (STS) are rare, potentially lethal extraskeletal mesenchymal neoplasms.
  • Approximately 12,000 US cases and 3,500 deaths occur annually.
  • Current therapeutic understanding relies heavily on trials from the 1980s and 1990s.

Purpose of the Study:

  • To summarize previously presented trials on soft tissue sarcoma management.
  • To critically assess recent publications addressing STS therapy.
  • To provide an updated perspective on managing soft tissue sarcomas.

Main Methods:

  • Review of seminal randomized controlled trials (RCTs) from the 1980s and 1990s.
  • Critical analysis of recent publications on STS management.
  • Synthesis of existing data to inform current therapeutic strategies.

Main Results:

  • Few new randomized controlled trials (RCTs) have been published recently.
  • The foundational understanding of STS biology and treatment remains largely based on older studies.
  • Recent literature provides incremental updates rather than paradigm shifts in STS management.

Conclusions:

  • Effective management of soft tissue sarcomas (STS) still heavily relies on established evidence from decades past.
  • There is a need for more contemporary randomized controlled trials (RCTs) in STS.
  • A critical evaluation of recent literature is essential for optimizing current STS treatment protocols.